Aeroscope Technologies (AIRS) Q4 2025: Skin Removal Pilot Hits 100 Procedures, Unlocking $100M+ Growth Channel
Aeroscope Technologies ended 2025 with stabilizing core revenue and a strategic pivot toward high-growth skin removal and tightening services, marking a return to positive same-store sales in early 2026. Key operational and cost discipline moves, including debt reduction and streamlined service offerings, are now feeding improved margins and a stronger balance sheet. The company’s focus on expanding its GLP-1-adjacent procedures and amplified marketing signals a deliberate shift to capture sizable new market demand as consumer trends evolve.
Summary
- GLP-1 Procedures Drive Expansion: Early traction in skin removal and tightening is broadening Aeroscope’s total addressable market.
- Cost Discipline Yields Margin Recovery: Operational streamlining and debt paydown have improved financial flexibility and profitability.
- Momentum Building into 2026: Same-store sales inflected positive, setting the stage for comp growth and new service ramp-up.
Performance Analysis
Aeroscope Technologies closed 2025 with sequential improvement in same-store sales, reversing earlier declines and achieving positive comps by February 2026. Revenue for Q4 landed at $33.4 million, reflecting a 15% YoY decline, but the contraction was offset by a notable 2% gross margin expansion to 59% as cost of services fell faster than revenue. This margin recovery was a direct result of cost containment, operational simplification, and targeted reinvestment in growth initiatives. Adjusted EBITDA for the quarter rose both in dollars and as a percentage of sales, with operational leverage evident in SG&A reductions and a flat customer acquisition cost per case.
On a full-year basis, revenue came in at $151.8 million with adjusted EBITDA margin at 10%. The company ended the year with cash of $8.4 million and further reduced debt, leveraging proceeds from an at-the-market equity facility to bring net leverage below 2.5x. Cash flow from operations, while down from the prior year, remained positive. The company’s decision to exit its only non-North American clinic and focus on core geographies also contributed to a leaner, more resilient operational base.
- Revenue Inflection: Same-store sales improved from down 22% to positive territory by February 2026.
- Margin Expansion: Cost of services and SG&A reductions drove a 2% gross margin gain and higher EBITDA margin.
- Debt Reduction: Over $30 million in debt paid down across five quarters, supporting liquidity and compliance.
Momentum in lead and consult volumes is translating to improved revenue trends as the company enters its busiest period, underpinned by new service introductions and enhanced marketing effectiveness.
Executive Commentary
"Our core business has stabilized, with same-store sales improving from down 22% at the start of 2025 to positive in Feb 2026. Our trends continued favorably in March, and we expect Q1 same-store sales to be flat, which would be the midpoint of the revenue range previously provided. As we prepare for our busiest quarter, we are seeing broad-based improvement in revenue across our centers. This improvement is tied directly to the actions we took starting in Q4."
Yogi Jasmany, Chief Executive Officer
"Airsculpt combines strong unit-level performance, a differentiated offering, and a brand with the right to win in a growing aesthetics market. With attractive clinic-level contribution margins and a significant white space for expansion, both geographically and across adjacent procedures, the platform is well-positioned for sustained, scalable growth."
Michael Arthur, Chief Financial Officer
Strategic Positioning
1. GLP-1-Driven Service Expansion
GLP-1 medications, drugs for weight loss and diabetes, are reshaping consumer demand in aesthetics by increasing the need for skin tightening and removal post-weight loss. Aeroscope’s rollout of standalone skin tightening and a skin excision pilot has unlocked a $100 million-plus long-term sales opportunity, with over 100 skin removal surgeries performed in Q4. These new procedures leverage existing clinic capacity and talent, supporting higher center utilization and productivity.
2. Enhanced Sales and Marketing Engine
Marketing investments in connected TV, influencer partnerships, and digital conversion optimization have begun to yield measurable gains in lead volumes and patient engagement. Campaigns focused on new service lines are raising awareness and driving conversion, while improved patient financing options (with full upfront payment retained) remove friction from the sales process.
3. Financial Discipline and Capital Allocation
Debt reduction remains the top capital allocation priority, with over $30 million paid down in five quarters and leverage below 2.5x. Cost actions delivered $4 million in annualized savings in 2025, enabling selective reinvestment in growth. The company’s exit from its London clinic and focus on North American operations further streamlines the business for margin resilience.
4. Talent and Leadership Infusion
Key executive hires in finance, legal, and operations bring multi-unit and turnaround expertise, strengthening the leadership bench and supporting execution of the growth agenda. The new CFO’s background in operational turnarounds and private transactions signals a focus on sustainable profitability and disciplined expansion.
Key Considerations
Aeroscope’s 2025 results and early 2026 trends reflect a business in transition, stabilizing its core while pivoting to high-growth, GLP-1-adjacent opportunities. The company is balancing cost discipline with targeted investment to drive a durable growth trajectory.
Key Considerations:
- GLP-1 Ecosystem Leverage: The company’s skin tightening and removal offerings position it as a direct beneficiary of the post-GLP-1 weight loss trend, expanding its serviceable market beyond traditional body contouring.
- Marketing ROI Inflection: Enhanced digital and influencer campaigns are driving higher consult and lead volumes, supporting future revenue conversion.
- Operational Streamlining: Exiting non-core geographies and reducing fixed cost base has improved margin structure and agility.
- Balance Sheet Optionality: Debt reduction and improved liquidity provide flexibility to reinvest or weather macro volatility.
- Supply Chain Watchpoint: The company flagged potential risk from global healing plasma shortages due to geopolitical events, which could impact skin tightening procedures if not resolved.
Risks
Consumer discretionary trends remain volatile, posing ongoing risk to procedure volumes if macro conditions deteriorate. Global supply chain constraints for healing plasma, a key input for skin tightening, could disrupt service delivery if the Iran conflict persists. Execution risk exists around the ramp-up of new procedures and the scalability of marketing ROI, while any missteps in financial controls, as highlighted by the recent lease accounting restatement, could undermine investor confidence.
Forward Outlook
For Q1 2026, Aeroscope guided to:
- Flat same-store sales, reflecting stabilization and sequential improvement
- Revenue in line with the midpoint of the previously provided range
For full-year 2026, management maintained guidance:
- Revenue of $151 to $157 million, implying approximately 3% comp growth at the midpoint (excluding London)
- Adjusted EBITDA of $15 to $17 million, with margin expansion from cost actions and targeted reinvestment
Management highlighted:
- Momentum in new service adoption and marketing-driven lead generation
- No new center openings planned in 2026, with focus on maximizing existing clinic productivity
- Active monitoring of healing plasma supply disruptions and readiness to adjust as needed
Takeaways
Aeroscope’s turnaround is gaining traction, with clear signals of stabilization and early success in new, high-demand service lines.
- Growth Engine Reset: The company’s pivot toward skin tightening and removal, coupled with targeted marketing, is beginning to drive incremental demand and sets up a multi-year growth runway.
- Margin and Balance Sheet Strength: Cost discipline and debt reduction have restored financial flexibility, enabling Aeroscope to reinvest in high-ROI initiatives without overextending risk.
- Execution Watchpoints: Investors should monitor the pace of new procedure adoption, supply chain developments, and the sustainability of marketing-driven lead generation as the year unfolds.
Conclusion
Aeroscope Technologies enters 2026 with positive momentum, a refocused service portfolio, and a stronger balance sheet. The company’s deliberate push into GLP-1-adjacent procedures and disciplined capital management position it for comp growth and margin expansion, though sustained execution and supply chain vigilance will be key to realizing its full potential.
Industry Read-Through
Aeroscope’s results underscore a broader shift in the aesthetics industry as GLP-1 adoption reshapes consumer demand for post-weight loss procedures. Providers with the ability to quickly add adjacent services and leverage digital marketing are best positioned to capture this new demand curve. Margin recovery through operational streamlining and selective reinvestment is likely to become a playbook for other elective procedure businesses facing similar macro headwinds. The highlighted supply chain risks for specialty medical inputs also signal a need for proactive sourcing strategies across the sector.